After years of legislative gridlock, federal policymakers have enacted sweeping reforms targeting pharmacy benefit managers (PBMs). Newly signed legislation will prohibit PBM compensation structures tied to drug list prices, require greater transparency into PBM business practices, and mandate that manufacturer rebates be passed through to plan sponsors and patients. In parallel, the U.S. Department of Labor proposed a rule that would require PBMs to disclose additional information to employer-sponsored health plans, including details about rebates, pharmacy reimbursement rates, and compensation arrangements.
Together, these developments represent one of the most significant regulatory shifts the PBM industry has faced in decades. The changes are expected to reshape how PBMs structure their revenue models and how employers, plan sponsors, and regulators evaluate PBM performance within the pharmaceutical supply chain.
According to Frier Levitt Partner Jesse Dresser, the new framework marks a fundamental turning point for the industry.
“It’s kind of a paradigm shift in terms of what the marketplace is going to expect from PBMs going forward.”
While many large PBMs have already begun moving toward more transparent pricing structures in response to growing scrutiny, the new federal requirements will further pressure the industry to demonstrate value while adapting to new compliance obligations. Stakeholders across the healthcare supply chain, including pharmacies, plan sponsors, and manufacturers, should closely monitor how PBMs adjust their contracting models and pricing strategies as these reforms take effect.
Read the full article (subscription required).
